VERU$2.11-2.31%
Veru Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$35.98M
Float & O/S:
Inst Own:
DilutionScan read 9 of VERU INC.'s SEC filings and found 3 warrant series, 2 ATM programs, 1 equity line, 3 shelf registrations and 1 completed offering on file for VERU. The latest dilution event on file is ATM sales on Jul 2, 2026. Analysis updated Sep 8, 2026.
Signal8 Summary
VERU
Clinical-stage biotech with tight cash runway
Snapshot
Veru is a clinical-stage biopharma that reported $0 in revenue for fiscal 2025 (down from $16.9M the prior year) and a $22.7M net loss, burning roughly $30M in cash from operations.
What's Happening Right Now
- : Fiscal Q3 net loss narrowed to $7.0M ($0.30/share) and cash rose to $23.9M, while the Phase 2b PLATEAU obesity trial finished enrolling 239 patients with interim results due Q1 2027.
- : Veru received a USPTO Notice of Allowance for a patent covering enobosarm combined with semaglutide for weight loss, giving protection until at least October 2044 once issued.
- : Veru announced full enrollment (about 200+ patients) in its Phase 2b PLATEAU study testing enobosarm plus semaglutide for weight loss in older adults, with final topline data expected Q4 2027.
